JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has reiterated its Market Outperform rating on OptimizeRx (NASDAQ: OPRX) and maintained a price target of $16.
June 24, 2024 | 3:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating on OptimizeRx and maintained a price target of $16.
The reiteration of a Market Outperform rating and a maintained price target of $16 by JMP Securities is a positive signal for investors. It suggests confidence in the company's future performance, which could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100